Financial Statements 27 demerger of rB Pharmaceuticals continued net income and Cashflows from discontinued operations RB Pharmaceuticals has been presented as a discontinued operation because it is no longer controlled by the Group and represents a major line of business.
Financial information relating to the operations of RB Pharmaceuticals for the period is set out below.
The Group Income Statement and Group Cash Flow Statement distinguish discontinued operations from continued operations.
Comparative figures have been restated.
The financial performance and cash flow information presented are for the period to 23 December 2014 and the year ended 31 December 2013.
2014 2013 For the year ended 31 december m m Revenue 677 777 Expenses 308 319 Profit before income tax 369 458 Income tax expense 91 121 net income from discontinued operations 278 337 The major classes of cash flows related to RB Pharmaceuticals are as follows: 2014 2013 For the year ended 31 december m m Cash flows from operating activities 223 446 Cash flows from investing activities 16 1 Cash flows from financing activities 481 net increase in cash and cash equivalents from discontinued operations 688 445 28 dividends 2014 2013 m m Cash dividends on equity ordinary shares: 2013 Final paid: 77p 2012: Final 78p per share 554 561 2014 Interim paid: 60p 2013: Interim 60p per share 434 431 988 992 non-cash dividends on equity ordinary shares: Fair value of non-cash dividend 1,046 Total dividends for the year 2,034 992 On 23 December 2014 the pharmaceutical business was demerged by means of a non-cash dividend, granting all Reckitt Benckiser Group plc ordinary Shareholders new shares in the newly formed Indivior PLC.
The transaction was recognised and measured in accordance with IFRIC 17 Distribution of Non-cash Assets to Owners.
In addition, the Directors are proposing a final cash dividend in respect of the financial year ended 31 December 2014 of 79p per share which will absorb an estimated 568m of Shareholders funds.
If approved by Shareholders it will be paid on 29 May 2015 to Shareholders who are on the register on 17 April 2015, with an ex-dividend date of 16 April 2015.
29 Post Balance Sheet events On 11 February 2015, we announced our intention to supplement the current share buyback policy with an additional share buyback programme in 2015 of up to 500m.
This, combined with the previous share buyback programme announced in 2014, will absorb approximately 800m of Shareholders funds.
In addition, after 31 December 2014, the Group reorganised the geographical organisational structure to comprise two operating segments ENA and Developing Markets DVM.
ENA will comprise the geographies of Europe, Russia CIS, Israel, North America, Australia, and New Zealand.
DVM will combine the historic RUMEA and LAPAC, with the exception of those countries above now being reported in ENA.
This will impact the operating segments for 2015.
RB Annual Report and Financial Statements 2014 115
